|
A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial. |
|
|
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Immunicum |
Speakers' Bureau - Blueprint Medicines |
Research Funding - Karyopharm Therapeutics (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Pfizer; PharmaMar |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; DAICHII; Eisai; GlaxoSmithKline; Lilly; Novartis; Pfizer; PharmaMar; Roche; Seagen |
Speakers' Bureau - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; PharmaMar; Roche |
Travel, Accommodations, Expenses - Novartis; PharmaMar |
|
|
Consulting or Advisory Role - Eisai; PharmaMar; Sanofi |
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck; PharmaMar; PharmaMar |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche |
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche |
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar |
|
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |